Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus RFA vs TACE alone for HCC with PVTT
NCT02301091Phase 3Unknown
- Start
- Oct 2014
- Primary completion
- Oct 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms). Primary endpoint: Overall survival rates at 1 year. Status: unknown.
Beyond the preview
Go deeper on NCT02301091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301091.